| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1046151382 |
| P356 | DOI | 10.1038/SJ.KI.5001630 |
| P698 | PubMed publication ID | 16820790 |
| P50 | author | Hans C. van Houwelingen | Q59660364 |
| P2093 | author name string | R H W M Derksen | |
| J J Weening | |||
| M Bijl | |||
| J A Bruijn | |||
| K J Assmann | |||
| G Ligtenberg | |||
| E C Hagen | |||
| C Grootscholten | |||
| J H M Berden | |||
| Dutch Working Party on Systemic Lupus Erythematosus | |||
| A W L van den Wall Bake | |||
| J W de Glas-Vos | |||
| P2860 | cites work | The 1982 revised criteria for the classification of systemic lupus erythematosus | Q29547225 |
| Prediction of creatinine clearance from serum creatinine | Q29615603 | ||
| Systemic lupus erythematosus: emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease | Q33489732 | ||
| Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide | Q33578853 | ||
| Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis | Q34244145 | ||
| Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials | Q35642238 | ||
| Preventing renal failure in patients with severe lupus nephritis | Q36063980 | ||
| Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data | Q36748174 | ||
| Current treatment recommendations for lupus nephritis | Q37949332 | ||
| Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies | Q40646509 | ||
| Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis | Q43936753 | ||
| Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide | Q43993205 | ||
| Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. | Q44441787 | ||
| Sequential therapies for proliferative lupus nephritis | Q44785533 | ||
| Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis | Q44826001 | ||
| Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial | Q45184210 | ||
| Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus | Q46687330 | ||
| Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis | Q46818795 | ||
| "Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis. | Q50988300 | ||
| Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy. | Q53633371 | ||
| The classification of glomerulonephritis in systemic lupus erythematosus revisited | Q58482164 | ||
| Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only | Q67925070 | ||
| A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group | Q68102206 | ||
| Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs | Q68859513 | ||
| Controlled studies of oral immunosuppressive drugs in lupus nephritis. A long-term follow-up | Q70261365 | ||
| Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome | Q70624757 | ||
| Effect of treatment on the evolution of renal abnormalities in lupus nephritis | Q71438057 | ||
| Treatment of proliferative lupus nephritis with methylprednisolone pulse therapy and oral azathioprine | Q72596589 | ||
| Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy | Q72849010 | ||
| Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group | Q73088409 | ||
| Lupus nephritis | Q73604873 | ||
| Long-term efficacy of azathioprine treatment for proliferative lupus nephritis | Q74312793 | ||
| Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy | Q74552382 | ||
| Patient preferences for treatment of lupus nephritis | Q74714779 | ||
| The very long-term prognosis and complications of lupus nephritis and its treatment | Q77970423 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 732-742 | |
| P577 | publication date | 2006-07-05 | |
| P1433 | published in | Kidney International | Q6404823 |
| P1476 | title | Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial | |
| P478 | volume | 70 |
| Q39418115 | A comparative study of two intensified pulse cyclophosphamide remission-inducing regimens for diffuse proliferative lupus nephritis: an Egyptian experience. |
| Q42511206 | A decade of mycophenolate mofetil for lupus nephritis: is the glass half-empty or half-full? |
| Q41919273 | A prospective study of anti-chromatin and anti-C1q autoantibodies in patients with proliferative lupus nephritis treated with cyclophosphamide pulses or azathioprine/methylprednisolone |
| Q41673025 | Acetylated Histones in Apoptotic Microparticles Drive the Formation of Neutrophil Extracellular Traps in Active Lupus Nephritis. |
| Q36221407 | American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis |
| Q37378976 | An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseases |
| Q55314394 | Analysis of clinical risk factors in relapsed patients with class IV lupus nephritis. |
| Q36174201 | Autoantibodies against Modified Histone Peptides in SLE Patients Are Associated with Disease Activity and Lupus Nephritis. |
| Q87393398 | Chapter 12: Lupus nephritis |
| Q37892917 | Clearing the complexity: immune complexes and their treatment in lupus nephritis |
| Q52873079 | Clinical and Histopathologic Characteristics Associated with Renal Outcomes in Lupus Nephritis. |
| Q55691902 | Clinicopathological characteristics and outcomes of Chinese patients with scanty immune deposits lupus nephritis: a large cohort study from a single center. |
| Q45239422 | Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis |
| Q36278355 | Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus |
| Q33882751 | Current status of lupus nephritis |
| Q34095231 | Cyclophosphamide and lupus nephritis: when, how, for how long? |
| Q36392336 | Developments in lupus 2006 |
| Q37804548 | Drug Monitoring in Systemic Lupus Erythematosus: A Systematic Review |
| Q35051164 | ESRD from lupus nephritis in the United States, 1995-2010 |
| Q35025425 | Early change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset |
| Q34490782 | Efficacy of long-term maintenance therapy with mycophenolate mofetil in lupus nephritis |
| Q57689077 | Immunosuppressive treatment for proliferative lupus nephritis |
| Q36302245 | Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis |
| Q84651003 | Lack of Association of C-C Chemokine Receptor 5 Δ32 Deletion Status with Rheumatoid Arthritis, Systemic Lupus Erythematosus, Lupus Nephritis, and Disease Severity |
| Q95592748 | Lupus nephritis |
| Q37399315 | Lupus nephritis in children - 10 years' experience. |
| Q91675894 | Mesenchymal Stem Cells: Allogeneic MSC May Be Immunosuppressive but Autologous MSC Are Dysfunctional in Lupus Patients |
| Q89702114 | Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology |
| Q36680040 | National trends in pediatric systemic lupus erythematosus hospitalization in the United States: 2000-2009 |
| Q50616527 | Persistent hypertension in lupus nephritis and the associated risk factors. |
| Q46171598 | Pro32Thr polymorphism of inosine triphosphate pyrophosphatase gene predicts efficacy of low-dose azathioprine for patients with systemic lupus erythematosus |
| Q33924437 | Recent clinical trials in lupus nephritis |
| Q57945954 | References |
| Q36257238 | Renal Interstitial Arteriosclerotic Lesions in Lupus Nephritis Patients: A Cohort Study from China |
| Q55215256 | Risk of adverse events from different drugs for SLE: a systematic review and network meta-analysis. |
| Q35667562 | Significant Reductions in Mortality in Hospitalized Patients with Systemic Lupus Erythematosus in Washington State from 2003 to 2011 |
| Q44108515 | Statement on the use of mycophenolate mofetil for systemic lupus erythematosus |
| Q93193261 | Systemic lupus erythematosus: Diagnosis and clinical management |
| Q37587317 | TAC-TIC use of tacrolimus-based regimens in lupus nephritis |
| Q33405303 | The spectrum of renal thrombotic microangiopathy in lupus nephritis |
| Q38062341 | The treatment of systemic lupus proliferative nephritis |
| Q24202572 | Treatment for lupus nephritis |
| Q42728756 | Treatment of lupus nephritis |
| Q84127283 | Treatment of lupus nephritis |
| Q80089184 | Treatment of proliferative lupus nephritis: a changing landscape |
| Q37822658 | Treatment of proliferative lupus nephritis: a slowly changing landscape |
| Q38271125 | Treatment of severe lupus nephritis: the new horizon. |
| Q37288728 | Treatment options for proliferative lupus nephritis: an update of clinical trial evidence |
| Q36008840 | Understanding lupus nephritis: diagnosis, management, and treatment options |
| Q37255744 | Update on the management of lupus nephritis: let the treatment fit the patient |
| Q80146676 | Why rheumatologists should be involved in the treatment of lupus nephritis |
| Q89894663 | [Tapering and termination of immunosuppressive therapy : Systemic lupus erythematosus] |
Search more.